Marie Felldin1, John Mackay Søfteland1,2, Jesper Magnusson1, Jana Ekberg1, Kristjan Karason1,3, Andreas Schult1,3, Hillevi Larsson4,5, Mihai Oltean1,2, Vanda Friman6. 1. Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden. 2. Department of Surgery, Institute for Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. 3. Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. 4. Division of Respiratory Medicine and Allergology, Skåne University Hospital, Lund, Sweden. 5. Department of Clinical Sciences, Lund University, Lund, Sweden. 6. Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Abstract
BACKGROUND: Solid organ transplant (SOT) recipients may be more vulnerable to coronavirus disease 2019 (COVID-19). Data on the clinical course of COVID-19 in immunosuppressed patients are limited, and the optimal management strategy for these patients is yet unclear. METHODS: We present 53 SOT recipients (31 kidney transplant recipients, 8 liver transplant recipients, 5 heart transplant recipients, 5 lung transplant recipients, 3 liver-kidney transplant recipients, and 1 kidney-after-heart transplant recipient), transplanted at a Swedish high-volume transplant center and each diagnosed with COVID-19 between February 21, 2020 and June 22, 2020. Demographic, clinical, and treatment data were extracted from the electronic patient files. RESULTS: Patients reported fever (61%), cough (43%), diarrhea (31%), and upper respiratory symptoms (29%). The median age was 56 years, and 57% were male. According to severity, 55% had mild, 13% had moderate, 19% had severe, and 13% had critical disease. Thirty-seven patients (70%) were hospitalized, with 8 requiring intensive care. Thirteen of the 37 patients were initially managed as outpatients but later hospitalized. One patient received hydroxychloroquine, and no patients received antivirals. Antimetabolites and calcineurin inhibitors were held or reduced in two-thirds. Twenty-seven of 37 hospitalized patients (73%) received low-molecular-weight heparin. Five (13.5%) hospitalized patients died. Overall survival for the entire cohort was 90.5%. No rejection episodes were noted. CONCLUSIONS: Hospitalization, lowering of immunosuppression, and prophylactic anticoagulation were the most common therapeutic interventions for SOT recipients with COVID-19. A significant proportion of patients could be managed on an outpatient basis, while keeping a low threshold for admission. Mild and moderate disease forms seem to have a good outcome.
BACKGROUND: Solid organ transplant (SOT) recipients may be more vulnerable to coronavirus disease 2019 (COVID-19). Data on the clinical course of COVID-19 in immunosuppressed patients are limited, and the optimal management strategy for these patients is yet unclear. METHODS: We present 53 SOT recipients (31 kidney transplant recipients, 8 liver transplant recipients, 5 heart transplant recipients, 5 lung transplant recipients, 3 liver-kidney transplant recipients, and 1 kidney-after-heart transplant recipient), transplanted at a Swedish high-volume transplant center and each diagnosed with COVID-19 between February 21, 2020 and June 22, 2020. Demographic, clinical, and treatment data were extracted from the electronic patient files. RESULTS:Patients reported fever (61%), cough (43%), diarrhea (31%), and upper respiratory symptoms (29%). The median age was 56 years, and 57% were male. According to severity, 55% had mild, 13% had moderate, 19% had severe, and 13% had critical disease. Thirty-seven patients (70%) were hospitalized, with 8 requiring intensive care. Thirteen of the 37 patients were initially managed as outpatients but later hospitalized. One patient received hydroxychloroquine, and no patients received antivirals. Antimetabolites and calcineurin inhibitors were held or reduced in two-thirds. Twenty-seven of 37 hospitalized patients (73%) received low-molecular-weight heparin. Five (13.5%) hospitalized patientsdied. Overall survival for the entire cohort was 90.5%. No rejection episodes were noted. CONCLUSIONS: Hospitalization, lowering of immunosuppression, and prophylactic anticoagulation were the most common therapeutic interventions for SOT recipients with COVID-19. A significant proportion of patients could be managed on an outpatient basis, while keeping a low threshold for admission. Mild and moderate disease forms seem to have a good outcome.
Authors: Rebecca J Free; Pallavi Annambhotla; Ricardo M La Hoz; Lara Danziger-Isakov; Jefferson M Jones; Lijuan Wang; Senthil Sankthivel; Marilyn E Levi; Marian G Michaels; Wendi Kuhnert; David Klassen; Sridhar V Basavaraju; Ian T Kracalik Journal: Open Forum Infect Dis Date: 2022-05-02 Impact factor: 4.423
Authors: John M Søfteland; Gustav Friman; Bengt von Zur-Mühlen; Bo-Göran Ericzon; Carin Wallquist; Kristjan Karason; Vanda Friman; Jan Ekelund; Marie Felldin; Jesper Magnusson; Ida Haugen Löfman; Andreas Schult; Emily de Coursey; Susannah Leach; Hanna Jacobsson; Jan-Åke Liljeqvist; Ali R Biglarnia; Per Lindnér; Mihai Oltean Journal: Am J Transplant Date: 2021-05-06 Impact factor: 9.369
Authors: Gillian Hardman; Ruth Sutcliffe; Rachel Hogg; Lisa Mumford; Laura Grocott; Sarah-Jane Mead-Regan; Jane Nuttall; Stephanie Dunn; Philip Seeley; Stephen Clark; Richard Quigley; Nawwar Al-Attar; Karen Booth; John H Dark; Andrew J Fisher Journal: Clin Transplant Date: 2021-02-01 Impact factor: 3.456
Authors: Chia Wei Teoh; Marie-Michele Gaudreault-Tremblay; Tom D Blydt-Hansen; Aviva Goldberg; Steven Arora; Janusz Feber; Valerie Langlois; Michelle Ruhl; Veronique Phan; Catherine Morgan; Philip Acott; Lorraine Hamiwka Journal: Can J Kidney Health Dis Date: 2020-11-13